Education
About Us
Working with TipRanks
Follow Us
Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
SANN Stock Chart & Stats
CHF10.52
-CHF0.14(-0.88%)
At close: 4:00 PM EST
CHF10.52
-CHF0.14(-0.88%)
Day’s Range― - ―
52-Week RangeCHF7.21 - CHF17.76
Previous CloseN/A
Volume24.19K
Average Volume (3M)95.23K
Market Cap
$140.58M
Enterprise ValueCHF210.76M
Total Cash (Recent Filing)$18.40M
Total Debt (Recent Filing)$76.30M
Price to Earnings (P/E)2.6
Beta0.35
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding14,010,270
10 Day Avg. Volume100,934
30 Day Avg. Volume95,230
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.68
Price to Sales (P/S)4.02
P/FCF Ratio-4.41
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit35.80
Enterprise Value/Ebitda-6.48
Forecast
1Y Price Target
$30.00Price Target Upside185.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Distribution AgreementsAn exclusive distribution agreement for vamorolone has been established in Russia, allowing access to AGAMREE for Duchenne muscular dystrophy patients across the country.
Financial PerformanceSanthera expects FY2025 top-line revenue to exceed the previously stipulated guidance range, suggesting stronger financial performance.
Sales GrowthVamorolone direct sales growth is accelerating in Germany, with increasing use beyond the initial pediatric cohort and rising combination therapy with DUVYZAT™.
Bears Say
Market RisksRisks include, but are not limited to: setbacks with vamorolone in areas beyond DMD, partnership risks, slower-than-projected market uptake for vamorolone in the U.S. and EU, inability to optimize vamorolone's value in other countries and territories, currency risks due to a decline in the relative value of the U.S. dollar, and possible medium- to long-term dilution risk.
Santhera Pharmaceuticals Holding News
SANN FAQ
What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?
Santhera Pharmaceuticals Holding lowest stock price was CHF7.21 and its highest was CHF17.76 in the past 12 months.
What is Santhera Pharmaceuticals Holding’s market cap?
Santhera Pharmaceuticals Holding’s market cap is $140.58M.
When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?
Santhera Pharmaceuticals Holding’s upcoming earnings report date is Apr 23, 2026 which is in 183 days.
How were Santhera Pharmaceuticals Holding’s earnings last quarter?
Santhera Pharmaceuticals Holding released its earnings results on Sep 23, 2025. The company reported -CHF3.04 earnings per share for the quarter, missing the consensus estimate of -CHF0.6 by -CHF2.44.
Is Santhera Pharmaceuticals Holding overvalued?
According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Undervalued.
Does Santhera Pharmaceuticals Holding pay dividends?
Santhera Pharmaceuticals Holding does not currently pay dividends.
What is Santhera Pharmaceuticals Holding’s EPS estimate?
Santhera Pharmaceuticals Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Santhera Pharmaceuticals Holding have?
Santhera Pharmaceuticals Holding has 14,010,270 shares outstanding.
What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?
Santhera Pharmaceuticals Holding reported an EPS of -CHF3.04 in its last earnings report, missing expectations of -CHF0.6. Following the earnings report the stock price went down -14.141%.
Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?
Currently, no hedge funds are holding shares in CH:SANN
Company Description
Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
SANN Company Deck
SANN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.View all CH:SANN earnings summariesSANN Stock 12 Month Forecast
Average Price Target
CHF30.00
▲(185.17% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---